Some red flags when reading a prediction model paper - no sample size calc - no mention of missing data - dichotomania - any mention of class imbalance/smote/classifier - no assessment of calibration - AUC > 0.95 - no internal validation - no model or link to code #statstwitter

Are you all caught up on your HemOnc Pulse episodes? If not, this is the perfect weekend to check out the recent episodes, ft. hem-oncs like Jay Spiegel, Aditi Shastri, MD, Matthew J. Maurer, DMSc, Alan Skarbnik, and of course our host chadi nabhan MD, MBA, FACP. 🎧 buff.ly/3H0FATv

AMAZING. ⁦Andrew M. Evens, DO, MBA, MSc⁩ ⁦Matthew J. Maurer, DMSc⁩ & Dr. Parsons collected data on THOUSANDS of Hodgkin PTs from all over the WORLD to answer questions we couldn’t answer B4. The full story on #HealthcareUnfiltered. Checkout: hodgkinconsortium.com Link: podcasts.apple.com/us/podcast/hea…

Excited to report our new paper on FL, great work by Jordan Krull #lymsm Follicular lymphoma B cells exhibit heterogeneous transcriptional states with associated somatic alterations and tumor microenvironments: Cell Reports Medicine cell.com/cell-reports-m…

📈 Biostatisticians, lend us your expertise! ASH is seeking insights to enhance #hematology research. Your input is invaluable in driving meaningful advancements. Take our brief survey today! >> ow.ly/zESV50QOTKQ #biostatistics #statistics #statisticians #datascience

I always say YES to ASH and it has resulted in many rewarding opportunities to mentor others and grow in my own career. If you are a biostatistician with hematology expertise, take this survey!!!

Monumental effort by GLOW team in publishing the largest analysis of NLPHL to date and answering many key questions about age specific risks, the prognostic impact of variant patterns, and developing a new LP-IPS: ascopubs.org/doi/10.1200/JC… GLOW: Global nLPHL One Working Group Journal of Clinical Oncology Jamie Flerlage

A huge congratulations to Drs. Michael Sargent Binkley & Jamie Flerlage and the entire GLOW: Global nLPHL One Working Group team on publication of an NLPHL-specific prognostic score (LP-IPS) in Journal of Clinical Oncology. Deeply grateful to have participated in this high-impact study! #lymsm #NLPHLsm ascopubs.org/doi/pdf/10.120…

International Prognostic Score for Nodular Lymphocyte–Predominant Hodgkin Lymphoma: important work by my Wilmot Cancer Institute colleague Jamie Flerlage Journal of Clinical Oncology ascopubs.org/doi/full/10.12…

What clinicians should know about surrogate endpoints Nice work Côme Bommier Matthew J. Maurer, DMSc Many great examples woven into a thoughtful piece ashpublications.org/blood/article/… Blood Journal

The FDA ODAC voted in favor of the use of MRD-negativity as an endpoint for accelerated approval in #myeloma trials. Read more about the vote, with remarks from Chris Hourigan (Fralin Biomedical Research Institute), Ravi A Madan M.D. (National Cancer Institute), & Matthew J. Maurer, DMSc (Mayo Clinic). 📖 buff.ly/4aF8oxb

🎇 Today, Sunday, May 5 - #CincodeMayo - We officially launch Project 5 in 5: Crowdsourcing 5 clinically relevant questions for 5 pragmatic clinical trials! 💡 What's your clinical trial idea? Sign up and submit ideas here ➡️ shareyourvoice.ideascalegov.com/c/ #OCEProject5in5

🎇 Today, Sunday, May 5 - #CincodeMayo - We officially launch Project 5 in 5: Crowdsourcing 5 clinically relevant questions for 5 pragmatic clinical trials! 💡 What's your clinical trial idea? Sign up and submit ideas here ➡️ shareyourvoice.ideascalegov.com/c/ #OCEProject5in5

I agree there was lots of inconsistency in the following the image guidelines. This seems a bit too far a correction vs penalties for those who don’t follow abstract guidelines. I would always prefer to see a KM curve vs simply reporting HRs. ASH #ASH24

FINALLY OUT ! "What clinicians should know about surrogate end points in hematologic malignancies" A clinician-friendly review building a bridge between clinicians and surrogacy specialists. Written along with Matthew J. Maurer, DMSc and Jérôme Lambert. ashpublications.org/blood/article/…

The stat/epi crowd at #ASHCRTI! PSA: Treat your biostatistician well — they are important to your hematology research career! I’m thankful that ASH includes biostatisticians as faculty in their training programs. Matthew J. Maurer, DMSc

Great week at ASH Clinical Research Training Institute. Congrats to our rising stars - the future is bright! ⭐️🌟⭐️ Follow: Seda Tolu Laura Samples, MD Zulfa Omer Yun Kyoung Ryu #ASHCRTI

Check out our latest paper in Journal of Clinical Oncology on surrogacy of endpoints in 1L #CLL trials! Led by Florian Simon, we systematically studied the association of PFS and MRD with OS. Some findings in a brief 🧵 👇 ascopubs.org/doi/10.1200/JC…